No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CTLT240719P57500
- 3.50
- 0.000.00%
15min DelayClose Jun 28 15:58 ET
0.00High0.00Low
3.50Open3.50Pre Close0 Volume137 Open Interest57.50Strike Price0.00Turnover55.50%IV3.97%PremiumJul 19, 2024Expiry Date1.27Intrinsic Value100Multiplier19DDays to Expiry2.23Extrinsic Value100Contract SizeAmericanOptions Type-0.5367Delta0.0554Gamma16.07Leverage Ratio-0.0701Theta-0.0157Rho-8.62Eff Leverage0.0516Vega
Intraday
- 5D
- Daily
News
Catalent Is Maintained at Equal-Weight by Barclays
Catalent Is Maintained at Equal-Weight by Barclays
Catalent Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 11.99% Barclays $47 → $63 Maintains Equal-Weight 04/04/2024 12.88% Stephens & Co. → $63.5 Reite
Express News | Catalent : Barclays Raises Target Price to $63 From $47
Barclays Maintains Catalent(CTLT.US) With Hold Rating, Raises Target Price to $63
Barclays analyst Luke Sergott maintains $Catalent(CTLT.US)$ with a hold rating, and adjusts the target price from $47 to $63.According to TipRanks data, the analyst has a success rate of 39.9% and a t
Barclays Adjusts Catalent Price Target to $63 From $47
Catalent (CTLT) has an average rating of Hold and price targets ranging from $63 to $63.50, according to analysts polled by Capital IQ. Price: 56.57, Change: +0.41, Percent Change: +0.73
Sarepta Cut to Neutral at Citi on Risks to Valuation
Comments
I've been on the hunt for a low-risk, yet relatively high-yield investment strategy, and I'm sure many of you feel the same. 🤔While I'm hesitant to dive into stocks like $NVIDIA(NVDA.US$ , fearing the price might be peaking and a sudden drop is imminent, I also find the stable dividends of companies like $Coca-Cola(KO.US$ underwhelming for my limited capital. 💡 But recently, I stumbled upon the concept of diversified investing, wh...
20
The pharma giant $Eli Lilly and Co(LLY.US$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...
71
$Catalent(CTLT.US$ why drop
$Catalent(CTLT.US$ 👀63$ all set target
RECAP
Stocks Fall as Yields Rise
US stocks fell as yields rose after investors tempered expectations of interest rate cuts this year. Over the weekend, Federal Reserve Chairman Jerome Powell said policymakers are worried that inflation could rear its ugly head and reaccelerate if the central bank moves too soon in lowering borrowing costs.
The $S&P 500 Index(.SPX.US$ slipped 0.3%, while the tech-heavy $NASDAQ 100 Index(.NDX.US$ slid 0...
Stocks Fall as Yields Rise
US stocks fell as yields rose after investors tempered expectations of interest rate cuts this year. Over the weekend, Federal Reserve Chairman Jerome Powell said policymakers are worried that inflation could rear its ugly head and reaccelerate if the central bank moves too soon in lowering borrowing costs.
The $S&P 500 Index(.SPX.US$ slipped 0.3%, while the tech-heavy $NASDAQ 100 Index(.NDX.US$ slid 0...
23
Read more